A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer

Inclusion Criteria:

- Clinical diagnosis of adenocarcinoma of the prostate.

- Metastatic prostate cancer (positive bone scan or measurable disease).

- Progressive disease after androgen deprivation.

- No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor
given to control prostate cancer).

Exclusion Criteria:

- Other prior malignancy, except for adequately treated basal or squamous cell skin
cancer or superficial bladder cancer, or any other cancer from which the patient has
been disease-free for greater than or equal to 5 years.

- Previous occurrence of autoimmune disease.

- Active infection requiring therapy including HIV or chronic hepatitis.